| __timestamp | Agios Pharmaceuticals, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 660772000 |
| Thursday, January 1, 2015 | 35992000 | 736435000 |
| Friday, January 1, 2016 | 50714000 | 775266000 |
| Sunday, January 1, 2017 | 71124000 | 860348000 |
| Monday, January 1, 2018 | 114145000 | 814775000 |
| Tuesday, January 1, 2019 | 132034000 | 942821000 |
| Wednesday, January 1, 2020 | 149070000 | 985616000 |
| Friday, January 1, 2021 | 121445000 | 1061508000 |
| Saturday, January 1, 2022 | 121673000 | 1190423000 |
| Sunday, January 1, 2023 | 119903000 | 1254234000 |
| Monday, January 1, 2024 | 156784000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical landscape, understanding spending patterns is crucial. Grifols, S.A. and Agios Pharmaceuticals, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Grifols consistently outspent Agios in Selling, General, and Administrative (SG&A) expenses. Grifols' SG&A expenses grew from approximately €661 million in 2014 to over €1.25 billion in 2023, marking a 90% increase. In contrast, Agios saw a more dramatic rise, with expenses surging from around €19 million to €120 million, a staggering 530% increase. This disparity highlights Grifols' established market presence and Agios' rapid growth trajectory. As Grifols consolidates its position, Agios is aggressively expanding, reflecting different strategic priorities. These insights underscore the dynamic nature of the pharmaceutical industry, where spending patterns reveal much about a company's strategy and market position.
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Xenon Pharmaceuticals Inc. and Agios Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.